Pályázati hírlevél
2014/34.
Tisztelettel felhívjuk figyelmét az alábbi pályázati felhívásokra, és hírekre. Kérjük,
szíveskedjen megadni azoknak a munkatársaknak a nevét és e-mail elérhetőségét, akik
számára fontos lehet a hírlevél közvetlen eljuttatása.
Üdvözlettel,
Semmelweis Egyetem
Innovációs Központ
1085 Budapest, Üllői út 26.
A Magyar Tudományos Akadémia pályázati felhívása új Lendületkutatócsoportok létrehozására 2015–2020
Célja:
A Lendület program a kiválóság és a mobilitás együttes támogatására irányul, ennek
megfelelően célja, hogy a befogadó kutatóhelyeken új téma kutatására alakuló
kutatócsoportok számára biztosítson forrást.
A pályázat benyújtására jogosultak köre:
Lendület I. - Önálló kutatói pályát kezdők kategóriája: 38 év alatti, kiemelkedő és
folyamatosan növekvő teljesítményt mutató, ígéretes fiatal kutatók.
Lendület II. - Sikeres önálló kutatói pályát folytatók kategóriája: 35-45 év közötti,
nemzetközileg is elismert, tartósan kiemelkedő és növekvő teljesítményű vezető kutatók.
A támogatás:
Minimális összege: évi 20 M Ft, maximális összege az I. kategóriában évi 50, a II.
kategóriában évi 60 M Ft lehet.
A pályázati anyagok feltöltésének határideje:
2015. január 13., 12.00 (közép-európai idő szerint).
Bővebb információk:
http://mta.hu/lendulet/?node_id=26716
IMI 2 - Call 3: Stage 1
H2020-JTI-IMI2-2015-03-two-stage
Research related to the future of medicine should be undertaken in areas where societal,
publichealth and biomedical industry competitiveness goals are aligned and require the
pooling of resources and greater collaboration between the public and private sectors, with the
involvement of small and medium-sized enterprises (SMEs).
Who can apply:
1) Legal entities established in a Member State or an associated country, or created under
Union law; and
2) which fall within one of the following categories:
- micro, small and medium-sized enterprises and other companies with an annual turnover of
EUR 500 million or less, the latter not being affiliated entities of companies with an annual
turnover of more than 500 million; the definition of ‘affiliated entities’ within the meaning of
Article 2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;
- secondary and higher education establishments;
- non-profit organisations, including those carrying out research or technological development
as one of their main objectives or those that are patient organisations.
3) The Joint Research Centre;
4) International European interest organisations.
Topics:
Topic 1: Remote assessment of disease and relapse – CNS,
Topic 2: Towards a quantitative biological approach for neuropsychiatry,
Topic 3: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease
modification,
Topic 4: The consistency approach to quality control in vaccine manufacture,
Topic 5: Pertussis vaccination research,
Topic 6: Knowledge repository to enable patient focused medicine development.
Indicative budget:
From EFPIA companies and IMI2 Associated Partners: EUR 56 430 000
From the IMI2 JU: EUR 56 430 000.
Deadline: 24 March 2015 – 17:00:00 Brussels time.
Other informations:
http://www.imi.europa.eu/content/stage-1-14
IMI 2 - Call 4: Stage 1
H2020-JTI-IMI2-2015-04-two-stage
Research related to the future of medicine should be undertaken in areas where societal,
public health and biomedical industry competitiveness goals are aligned and require the
pooling of resources and greater collaboration between the public and private sectors, with the
involvement of small and mediumsized enterprises (SMEs).
Who can apply:
1) Legal entities established in a Member State or an associated country, or created under
Union law; and
2) which fall within one of the following categories:
- micro, small and medium-sized enterprises and other companies with an annual turnover of
EUR 500 million or less, the latter not being affiliated entities of companies with an annual
turnover of more than 500 million; the definition of ‘affiliated entities’ within the meaning of
Article 2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;
- secondary and higher education establishments;
- non-profit organisations, including those carrying out research or technological development
as one of their main objectives or those that are patient organisations.
3) The Joint Research Centre;
4) International European interest organisations.
Topic:
Enabling Platform on Medicines Adaptive Pathways to Patients.
Indicative budget:
From EFPIA companies: EUR 1 130 000
From the IMI2 JU: EUR 1 130 000.
Deadline: 11 February 2015 – 17:00:00 Brussels time.
Other informations:
http://www.imi.europa.eu/content/stage-1-15
7th Joint call for European research projects on rare diseases
(JTC 2015)
The aim:
The aim of the call is to enable scientists in different countries to build an effective
collaboration on a common interdisciplinary research project based on complementarities and
sharing of expertise, with a clear translational research approach.
Who can apply:
Joint research proposals may be submitted by higher education institutions, non-university
public research establishments, hospitals as well as commercial companies, in particular small
and medium-size enterprises (SMEs), according to relevant national funding organisations´
regulations for research funding.
Topics:
Transnational research proposals must cover at least one of the following areas, which are
equal in relevance for this call:
- Collaborative research using patient databases and corresponding collections of biological
material that would generally not be possible at a national scale. This research must have clear
potential for clinical application and well defined scientific objectives e.g.:
- definition of new nosological entities, epidemiological studies, genotype/phenotype
correlations, natural history of diseases;
- characterisation of genetic/molecular basis of specific diseases
- Research on rare diseases including genetic, epigenetic and pathophysiological studies,
using innovative and shared resources, technologies (OMICS, new generation sequencing,
etc.) and expertises,
- Research on development of applications for diagnosis and therapies for rare diseases. This
may include indentification and characterization of (bio)-markers for diagnosis and prognosis,
development of innovative screening systems and diagonsitic tools, the generation of relevant
cellular and/or animal models, and preclinical studies using pharmacological, gene or cell
therapies.
Budget:
Mio €: 0.15
Approximative number of research groups that can be funded: 1 – 2.
Deadline for pre-proposals: February 18, 2015.
Other informations:
http://www.erare.eu/joint-call/7th-joint-call-european-research-projects-rare-diseases-jtc-2015
COST Open Call
COST aims to enable breakthrough scientific developments leading to new concepts and
products.
Who can apply:
The COST Action is a pan-European network instrument allowing researchers from COST
Member Countries and Cooperating State to develop jointly their ideas and new initiatives in
a given field or topic of common interest on the basis of mutual benefit. They are open to
researchers, engineers and scholars from other countries and leverage nationally funded
research activities. Proposals for a COST Action must represent a network of proposers from
at least 5 COST countries.
Research areas:
-
Joining research efforts and developing common S&T programmes by coordinating
nationally funded research activities led by pan-European, high quality, collaborative
S&T networks.
Building capacity by providing networking and leadership opportunities for emerging
talents and thereby strengthening and building up excellent S&T communities.
Addressing Societal Questions by promoting trans-disciplinary, new approaches and
topics and identifying early warning signals of unforeseen societal problems aiming at
contributing to Societal Challenges.
Strengthening COST Inclusiveness Policy by fostering better access and integration of
less research intensive countries’ researchers to the knowledge hubs of the European
Research Area aiming atcontributing to the Widening Pillar of Horizon 2020.
Budget:
Selected proposals for COST Actions will get a financial support in the range of EUR
130.000 p.a., normally.
Collection date: 24 March 2015.
Other informations:
http://www.cost.eu/participate/open_call
Tisztelt Hölgyem/Uram!
Ezúton szeretnénk tájékoztatni, hogy az EIT KIC pályázatban nyert az Innolife konzorcium,
melyben a SE is partner az Innostars csoportban.
Bővebb információk:
http://eit.europa.eu/sites/default/files/EIT%20Health%20-%20Factsheet%202014.pdf
Tisztelt Hölgyem/Uram!
Tisztelettel hívom fel figyelmét a „Canada Gairdner International Awards
2016” lehetőségre, melyről részleteket az alábbiakban illetve a csatolt kiírásban talál.
A jelölések benyújtásának határideje: 2015. október 1.
Canada Gairdner International Awards
These prestigious awards recognize and reward outstanding biomedical scientists who have
made breakthrough discoveries and original contributions to biomedicine. The goal of the
Foundation is to contribute through research to increased understanding of human biology and
disease. The Gairdner celebrates and inspires the scientific research process with winners
spanning the world.
The Foundation was established through the pioneering gift of James Gairdner in 1959, a man
who had always been active in the community and embodied a sense of social consciousness.
Having suffered from Arthritis and knowing the strain that many medical afflictions had on
individuals and society as a whole, he was inspired to make a difference by investing in the
advancement of research that was certain to have a positive impact on society.
Over fifty years later, the Gairdner Foundation has lived up to the original expectations of its
founder. It has gained an international reputation for its early recognition of medical
breakthroughs that have changed the way medicine is practiced. Over 300 Canada Gairdner
International Awards have been given to scientists from 15 countries; of these recipients, 82
have subsequently won the world-renown Nobel Prize. In 2008 the government of Canada
provided $20 million to endow the awards for future generations.
Semmelweis University is invited to nominate qualified scientists from any branch of
biomedicine for the 2016 Canada Gairdner International Award. The deadline is October 1,
2015. The award normally recognizes an original, seminal contribution or discovery rather
than a lifetime work and is valued at $100,000 CDN. Nominations in the field of translational
research are welcome too.
For
more
information
and
to
see
past
laureates
please
visit
our
website: http://www.gairdner.org/